Join to access to all OVN content. Join for Free
Coronavirus (COVID-19): Its Impact on Publication Planning (04/29/2020)
COVID-19 impact on medical publishing virtual congresses and conferences challenges in medical publications pandemic effect on scientific journals

Coronavirus (COVID-19): Its Impact on Publication Planning (04/29/2020)


Share This Article


Summary

The Coronavirus (COVID-19) pandemic has impacted nearly every facet of our personal and professional lives. Medical publication professionals are facing uncharted territory and uncertainty as to how long the impact will last.

With live congresses being canceled, postponed or transitioned to a virtual format, we must now make decisions to convert presentations to virtual format, ensure embargo and copyright policies are followed, and actively update publication plans. Publications may face delays because authors and peer reviewers are focusing on clinical care, and also because of data availability delays.

Please join us to hear a panel of experts discuss their experiences and views, review our membership survey results, and present case studies to help guide professionals through this unprecedented situation.

At the end of this session, participants should be able to:

  • Be knowledgeable of challenges to medical publishing stemming from the Coronavirus (COVID-19) pandemic
  • Be aware of how congresses and journal publishers are being affected
  • Modify publication plans appropriately in response to changing conditions
  • Maintain good publication practices and ethics in a rapidly shifting environment

Click for Source Download PDF version
COVID-19 impact on medical publishing, virtual congresses and conferences, challenges in medical publications, pandemic effect on scientific journals

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Article
Virtual Oncology MSL Team Increases KOL Engagement by 120%
Partner Avatar iNIZIO

Virtual Oncology MSL Team Increases KOL Engagement by 120%

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Explore OVN